



Commutability: Challenges in the harmonisation/standardisation of assays for autoimmune disorders

Evanthia Monogioudi

Joint Research Centre, European Commission

*Workshop on Measurement Challenges:
laboratory medicine*

10 November 2021

JRC's mission

“


*As the science and knowledge service
of the Commission our mission is to support
EU policies with independent evidence
throughout the whole policy cycle*

”



(Certified) Reference materials

- Biomarkers for health monitoring
- Genetically modified organisms (GMOs)
- Food additives, contaminants, ingredients, residues
- Environmental pollutants
- Nanomaterials & industrial materials
- ~ **680 different materials available**




Introduction: what is commutability

According to VIM, commutability is:

“a **property of an RM**, demonstrated by the closeness of agreement between the relation among the measurement results for a stated quantity in this material, obtained according to **2 given MPs**, and the relation obtained among the measurement results for other specified materials”

JCGM. 3rd. Sevres, France: International Bureau of Weights and Measures; 2012.
International vocabulary of metrology—basic and general concepts and associated terms (VIM)



- Patient samples
- Linear correlation
- - 95% prediction interval
- ▲ Commutable RM
- Non commutable RM

IFCC working group on commutability

Clinical Chemistry 64:3
447-454 (2018)

Special Reports



IFCC Working Group Recommendations for Assessing Commutability Part 1: General Experimental Design

W. Greg Miller,^{1*} Heinz Schimmel,² Robert Rej,³ Neil Greenberg,⁴ Ferruccio Ceriotti,⁵ Chris Burns,⁶ Jeffrey R. Budd,⁷ Cas Weykamp,⁸ Vincent Delatour,⁹ Göran Nilsson,¹⁰ Finlay MacKenzie,¹¹ Mauro Panteghini,¹² Thomas Keller,¹³ Johanna E. Camara,¹⁴ Ingrid Zegers,² and Hubert W. Vesper,¹⁵ for the IFCC Working Group on Commutability

Clinical Chemistry 64:3
455-464 (2018)

Special Reports



IFCC Working Group Recommendations for Assessing Commutability Part 2: Using the Difference in Bias between a Reference Material and Clinical Samples

Göran Nilsson,¹ Jeffrey R. Budd,² Neil Greenberg,³ Vincent Delatour,⁴ Robert Rej,⁵ Mauro Panteghini,⁶ Ferruccio Ceriotti,⁷ Heinz Schimmel,⁸ Cas Weykamp,⁹ Thomas Keller,¹⁰ Johanna E. Camara,¹¹ Chris Burns,¹² Hubert W. Vesper,¹³ Finlay MacKenzie,¹⁴ and W. Greg Miller,^{15*} for the IFCC Working Group on Commutability

Clinical Chemistry 64:3
465-474 (2018)

Special Reports



IFCC Working Group Recommendations for Assessing Commutability Part 3: Using the Calibration Effectiveness of a Reference Material

Jeffrey R. Budd,¹ Cas Weykamp,² Robert Rej,³ Finlay MacKenzie,⁴ Ferruccio Ceriotti,⁵ Neil Greenberg,⁶ Johanna E. Camara,⁷ Heinz Schimmel,⁸ Hubert W. Vesper,⁹ Thomas Keller,¹⁰ Vincent Delatour,¹¹ Mauro Panteghini,¹² Chris Burns,¹³ and W. Greg Miller,^{14*} for the IFCC Working Group on Commutability

Clinical Chemistry 66:6
769-778 (2020)

Special Report



IFCC Working Group Recommendations for Correction of Bias Caused by Noncommutability of a Certified Reference Material Used in the Calibration Hierarchy of an End-User Measurement Procedure

W. Greg Miller,^{a,*} Jeffrey Budd,^b Neil Greenberg,^c Cas Weykamp,^d Harald Althaus,^e Heinz Schimmel,^f Mauro Panteghini,^g Vincent Delatour,^h Ferruccio Ceriotti,ⁱ Thomas Keller,^j Douglas Hawkins,^k Chris Burns,^l Robert Rej,^m Johanna E. Camara,ⁿ Finlay MacKenzie,^o Eline van der Hagen,^d Hubert Vesper,^p for the IFCC Working Group on Commutability

Real life example: RM for anti-glomerular basement membrane (anti-GBM) disease

- IFCC C-HAT request
- Rare autoimmune condition responsible for rapidly progressive glomerulonephritis and/or lung bleeding
- IgG autoantibodies / non-collagenous domain of the $\alpha 3(\text{IV})$ collagen chain
- IgA or IgM anti-GBM antibodies



Challenges

- Method correlation
 - Antigen complexity/specificity
 - Antibody response
- Starting material CRM
 - Pooling donations is too risky
 - Large single donations (>1L) after plasmapheresis
- Commutability study
 - Clinical sample availability limited
 - Concentration range (often dilutions required)

Real life example: commutability of a RM for anti-GBM IgG

- 7 routine methods
- 30 clinical samples
 - Without known interferences
 - 2 reps/plate, 4 reps/total
- 5 candidate RMs
 - 2 dilutions (5 reps/dilution)
- 5 purified anti-GBM IgG antibodies
 - 2 reps/plate, 4 reps/total
- Statistical approach: Difference in bias (IFCC)

Method correlation (anti-GBM IgG)



x Clinical samples, ● RM A, ● RM B, ● RM C, ● pab RM A, ● pab RM B, ● pab RM C

Statistical analysis: difference in bias

Coverage factor:

depends on confidence level
and degrees of freedom

Standard uncertainty associated with average bias samples

Depends on number of samples

Variability among bias of individual samples (sample-specific effects)

$$U(d_{RM}) = k \times \sqrt{(u(B_{RM}))^2 + (u(\bar{B}_S))^2}$$

Standard uncertainty associated with bias RM:



Depends on repeatability of methods
and number of replicate measurements

Commutability Criterion

“the maximum accepted difference between the bias of the RM
and clinical samples”

1. $d_{RM} \pm U(d_{RM})$ is within $C \pm 0$ —————→ Commutable
2. $d_{RM} \pm U(d_{RM})$ is outside $C \pm 0$ —————→ Non-commutable
3. $d_{RM} \pm U(d_{RM})$ is overlapping with $C \pm 0$ —————→ Inconclusive

IFCC approach: Difference in bias



x Clinical samples,
 ● RM A,
 ● RM B,
 ● RM C,
 ● pab RM A,
 ● pab RM B,
 ● pab RM C

— Average bias
 - - - Commutability criteria
 ┘ Expanded uncertainty, difference in Bias

Conclusions

- Criterion
 - Same for each method comparison
 - Linked to intended use of CRM
- Sample-specific differences are rather large
- Too high uncertainty → Inconclusive results
- Large number clinical samples and measurements needed for conclusive results
- If several RM: difficult in one run

Conclusions

Possible solution: two step approach

Phase 1: study with many RM and large uncertainty

Phase 2: extended study with selected RM and smaller uncertainty

Keep in touch



You can find me at evanthia.monogioudi@ec.europa.eu



EU Science Hub: <https://ec.europa.eu/jrc>

Our reference materials catalogue: <https://crm.jrc.ec.europa.eu>



@EU_ScienceHub



EU Science Hub – Joint Research Centre



EU Science, Research and Innovation



Eu Science Hub

Thank you

© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.